These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 26314532)

  • 41. Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
    Giustino G; Redfors B; Mehran R; Kirtane AJ; Baber U; Généreux P; Witzenbichler B; Neumann FJ; Weisz G; Maehara A; Rinaldi MJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Dangas GD; Brener SJ; Ozgu Ozan M; Stone GW
    Int J Cardiol; 2017 Nov; 246():20-25. PubMed ID: 28867009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial.
    Jeger RV; Brunner-La Rocca HP; Hunziker PR; Tsakiris DA; Kaiser CA; Pfisterer ME;
    Clin Ther; 2009 Dec; 31(12):2886-93. PubMed ID: 20110027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence and Impact of Thrombocytopenia in Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents.
    Park S; Ahn JM; Kim TO; Park H; Cho SC; Kang DY; Lee PH; Park DW; Park SJ;
    Am J Cardiol; 2020 Nov; 134():55-61. PubMed ID: 32891400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
    Giustino G; Kirtane AJ; Généreux P; Baber U; Witzenbichler B; Neumann FJ; Weisz G; Maehara A; Rinaldi MJ; Metzger C; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Dangas GD; Francese DP; Litherland C; Mehran R; Stone GW
    Am J Cardiol; 2016 Jun; 117(11):1703-13. PubMed ID: 27067621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
    Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
    JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study).
    Redfors B; Chen S; Ben-Yehuda O; Huang X; Witzenbichler B; Weisz G; Liu Y; Brodie BR; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Mehran R; Stuckey TD; Kirtane AJ; Stone GW
    Am J Cardiol; 2019 Nov; 124(9):1380-1388. PubMed ID: 31477234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of in-hospital bleeding according to the Bleeding Academic Research Consortium classification on the long-term adverse outcomes in patients undergoing percutaneous coronary intervention.
    Yoon YH; Kim YH; Kim SO; Lee JY; Park DW; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):63-71. PubMed ID: 24282105
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
    Lee HJ; Yu CW; Hwang HK; Choi RK; Park JS; Li H; Ro YM
    Coron Artery Dis; 2013 Nov; 24(7):542-8. PubMed ID: 23994880
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of the HAS-BLED Score on Long-Term Outcomes After Percutaneous Coronary Intervention.
    Konishi H; Miyauchi K; Tsuboi S; Ogita M; Naito R; Dohi T; Kasai T; Tamura H; Okazaki S; Isoda K; Daida H
    Am J Cardiol; 2015 Aug; 116(4):527-31. PubMed ID: 26081068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study.
    Gao XF; Lu S; Ge Z; Zuo GF; Wang ZM; Wang F; Kong XQ; Chai DY; Chen SL; Zhang JJ
    BMC Cardiovasc Disord; 2018 May; 18(1):103. PubMed ID: 29793432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1242-9. PubMed ID: 24355114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry.
    Baber U; Mehran R; Kirtane AJ; Gurbel PA; Christodoulidis G; Maehara A; Witzenbichler B; Weisz G; Rinaldi MJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Xu K; Parise H; Brodie BR; Stuckey TD; Stone GW
    Circ Cardiovasc Interv; 2015 Jun; 8(6):e001683. PubMed ID: 26056248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Optimal platelet inhibition after coronary stent implantation. Current status].
    Silber S; Hoffmeister HM; Bode C
    Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
    Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
    J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Bleeding Risk on Type of Stent Used in Patients Presenting With Acute Coronary Syndrome.
    Alraies MC; Lee SY; Lipinski MJ; Buchanan K; Steinvil A; Rogers T; Koifman E; Gai J; Torguson R; Ben-Dor I; Satler LF; Pichard AD; Waksman R
    Am J Cardiol; 2017 Oct; 120(8):1272-1278. PubMed ID: 28826893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) registry beyond the SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) study.
    Gyöngyösi M; Christ G; Lang I; Kreiner G; Sochor H; Probst P; Neunteufl T; Badr-Eslam R; Winkler S; Nyolczas N; Posa A; Leisch F; Karnik R; Siostrzonek P; Harb S; Heigert M; Zenker G; Benzer W; Bonner G; Kaider A; Glogar D;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):718-27. PubMed ID: 19695539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Frequency and predictors of bleeding events after 2nd generation drug-eluting stent implantation differ depending on time after implantation.
    Honda Y; Yamawaki M; Mori S; Shirai S; Makino K; Tokuda T; Maruyama T; Takafuji H; Takama T; Tsutumi M; Sakamoto Y; Takimura H; Kobayashi N; Araki M; Hirano K; Sakai T; Ito Y
    J Cardiol; 2017 Apr; 69(4):632-639. PubMed ID: 27371500
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
    Xia JG; Qu Y; Shen H; Liu XH
    Coron Artery Dis; 2013 Sep; 24(6):522-6. PubMed ID: 23900046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.